6 results match your criteria: "Tianjin Medical University Metabolic Diseases Hospital and Tianjin Institute of Endocrinology[Affiliation]"
Real-time foot pressure monitoring using wearable smart systems, with comprehensive foot health monitoring and analysis, can enhance quality of life and prevent foot-related diseases. However, traditional smart insole solutions that rely on basic data analysis methods of manual feature extraction are limited to real-time plantar pressure mapping and gait analysis, failing to meet the diverse needs of users for comprehensive foot healthcare. To address this, we propose a deep learning-enabled smart insole system comprising a plantar pressure sensing insole, portable circuit board, deep learning and data analysis blocks, and software interface.
View Article and Find Full Text PDFPathol Res Pract
November 2019
NHC Key Laboratory of Hormones and Development (Tianjin Medical University), Tianjin Key Laboratory of Metabolic Diseases, Tianjin Medical University Metabolic Diseases Hospital and Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin, 300070, China.
Background: Gastric cancer (GC) is the fourth most prevalent malignant tumor and the second leading cause of cancer-related death around the world. Aberrant proliferation and metastasis are the mainspring of death in patients with GC. However, the specific mechanism of gastric cancer is far from being fully elucidated.
View Article and Find Full Text PDFDiabetes Ther
October 2019
Clinical College of Ophthalmology, Tianjin Medical University, Tianjin, China.
Hepatol Res
July 2019
NHC Key Laboratory of Hormones and Development (Tianjin Medical University), Tianjin Key Laboratory of Metabolic Diseases, Tianjin Medical University Metabolic Diseases Hospital and Tianjin Institute of Endocrinology, Tianjin, China.
Ther Clin Risk Manag
December 2018
Department of Metabolic Disease Management Center, Tianjin 4th Central Hospital, Tianjin, China,
Background: Raised serum uric acid (SUA) level is commonly observed in patients with type 2 diabetes mellitus (T2DM) and is associated with increased morbidity and mortality. Sodium-glucose cotransporter 2 inhibitor, a novel oral diabetic drug, might exert a potential hypouricemic effect. We evaluated the effects of dapagliflozin on SUA levels in hospitalized T2DM patients with inadequate glycemic control.
View Article and Find Full Text PDFDiabetes Ther
February 2019
BD Diabetes Care, Erembodegem, Belgium.
The original article can be found online.
View Article and Find Full Text PDF